Targeting mitochondrial dysfunction in CNS injury using Methylene Blue; still a magic bullet?

Hemendra J. Vekaria, Lora Talley Watts, Ai Ling Lin, Patrick G. Sullivan

Research output: Contribution to journalShort survey

10 Citations (Scopus)

Abstract

Complex, multi-factorial secondary injury cascades are initiated following traumatic brain injury, which makes this a difficult disease to treat. The secondary injury cascades following the primary mechanical tissue damage, are likely where effective therapeutic interventions may be targeted. One promising therapeutic target following brain injury are mitochondria. Mitochondria are complex organelles found within the cell, which act as powerhouses within all cells by supplying ATP. These organelles are also necessary for calcium cycling, redox signaling and play a major role in the initiation of cell death pathways. When mitochondria become dysfunctional, there is a tendency for the cell to loose cellular homeostasis and can lead to eventual cell death. Targeting of mitochondrial dysfunction in various diseases has proven a successful approach, lending support to mitochondria as a pivotal player in TBI cell death and loss of behavioral function. Within this mixed mini review/research article there will be a general discussion of mitochondrial bioenergetics, followed by a brief discussion of traumatic brain injury and how mitochondria play an integral role in the neuropathological sequelae following an injury. We will also give an overview of one relatively new TBI therapeutic approach, Methylene Blue, currently being studied to ameliorate mitochondrial dysfunction following brain injury. We will also present novel experimental findings, that for the first time, characterize the ex vivo effect of Methylene Blue on mitochondrial function in synaptic and non-synaptic populations of mitochondria.

Original languageEnglish (US)
Pages (from-to)117-125
Number of pages9
JournalNeurochemistry International
Volume109
DOIs
StatePublished - Oct 1 2017
Externally publishedYes

Fingerprint

Magic
Methylene Blue
Mitochondria
Wounds and Injuries
Cell Death
Organelles
Brain Injuries
Energy Metabolism
Oxidation-Reduction
Homeostasis
Therapeutics
Adenosine Triphosphate
Calcium
Research
Population

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Cell Biology

Cite this

Targeting mitochondrial dysfunction in CNS injury using Methylene Blue; still a magic bullet? / Vekaria, Hemendra J.; Talley Watts, Lora; Lin, Ai Ling; Sullivan, Patrick G.

In: Neurochemistry International, Vol. 109, 01.10.2017, p. 117-125.

Research output: Contribution to journalShort survey

Vekaria, Hemendra J. ; Talley Watts, Lora ; Lin, Ai Ling ; Sullivan, Patrick G. / Targeting mitochondrial dysfunction in CNS injury using Methylene Blue; still a magic bullet?. In: Neurochemistry International. 2017 ; Vol. 109. pp. 117-125.
@article{f611f7e555334e4b9ea594a94b2a8e64,
title = "Targeting mitochondrial dysfunction in CNS injury using Methylene Blue; still a magic bullet?",
abstract = "Complex, multi-factorial secondary injury cascades are initiated following traumatic brain injury, which makes this a difficult disease to treat. The secondary injury cascades following the primary mechanical tissue damage, are likely where effective therapeutic interventions may be targeted. One promising therapeutic target following brain injury are mitochondria. Mitochondria are complex organelles found within the cell, which act as powerhouses within all cells by supplying ATP. These organelles are also necessary for calcium cycling, redox signaling and play a major role in the initiation of cell death pathways. When mitochondria become dysfunctional, there is a tendency for the cell to loose cellular homeostasis and can lead to eventual cell death. Targeting of mitochondrial dysfunction in various diseases has proven a successful approach, lending support to mitochondria as a pivotal player in TBI cell death and loss of behavioral function. Within this mixed mini review/research article there will be a general discussion of mitochondrial bioenergetics, followed by a brief discussion of traumatic brain injury and how mitochondria play an integral role in the neuropathological sequelae following an injury. We will also give an overview of one relatively new TBI therapeutic approach, Methylene Blue, currently being studied to ameliorate mitochondrial dysfunction following brain injury. We will also present novel experimental findings, that for the first time, characterize the ex vivo effect of Methylene Blue on mitochondrial function in synaptic and non-synaptic populations of mitochondria.",
author = "Vekaria, {Hemendra J.} and {Talley Watts}, Lora and Lin, {Ai Ling} and Sullivan, {Patrick G.}",
year = "2017",
month = "10",
day = "1",
doi = "10.1016/j.neuint.2017.04.004",
language = "English (US)",
volume = "109",
pages = "117--125",
journal = "Neurochemistry International",
issn = "0197-0186",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Targeting mitochondrial dysfunction in CNS injury using Methylene Blue; still a magic bullet?

AU - Vekaria, Hemendra J.

AU - Talley Watts, Lora

AU - Lin, Ai Ling

AU - Sullivan, Patrick G.

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Complex, multi-factorial secondary injury cascades are initiated following traumatic brain injury, which makes this a difficult disease to treat. The secondary injury cascades following the primary mechanical tissue damage, are likely where effective therapeutic interventions may be targeted. One promising therapeutic target following brain injury are mitochondria. Mitochondria are complex organelles found within the cell, which act as powerhouses within all cells by supplying ATP. These organelles are also necessary for calcium cycling, redox signaling and play a major role in the initiation of cell death pathways. When mitochondria become dysfunctional, there is a tendency for the cell to loose cellular homeostasis and can lead to eventual cell death. Targeting of mitochondrial dysfunction in various diseases has proven a successful approach, lending support to mitochondria as a pivotal player in TBI cell death and loss of behavioral function. Within this mixed mini review/research article there will be a general discussion of mitochondrial bioenergetics, followed by a brief discussion of traumatic brain injury and how mitochondria play an integral role in the neuropathological sequelae following an injury. We will also give an overview of one relatively new TBI therapeutic approach, Methylene Blue, currently being studied to ameliorate mitochondrial dysfunction following brain injury. We will also present novel experimental findings, that for the first time, characterize the ex vivo effect of Methylene Blue on mitochondrial function in synaptic and non-synaptic populations of mitochondria.

AB - Complex, multi-factorial secondary injury cascades are initiated following traumatic brain injury, which makes this a difficult disease to treat. The secondary injury cascades following the primary mechanical tissue damage, are likely where effective therapeutic interventions may be targeted. One promising therapeutic target following brain injury are mitochondria. Mitochondria are complex organelles found within the cell, which act as powerhouses within all cells by supplying ATP. These organelles are also necessary for calcium cycling, redox signaling and play a major role in the initiation of cell death pathways. When mitochondria become dysfunctional, there is a tendency for the cell to loose cellular homeostasis and can lead to eventual cell death. Targeting of mitochondrial dysfunction in various diseases has proven a successful approach, lending support to mitochondria as a pivotal player in TBI cell death and loss of behavioral function. Within this mixed mini review/research article there will be a general discussion of mitochondrial bioenergetics, followed by a brief discussion of traumatic brain injury and how mitochondria play an integral role in the neuropathological sequelae following an injury. We will also give an overview of one relatively new TBI therapeutic approach, Methylene Blue, currently being studied to ameliorate mitochondrial dysfunction following brain injury. We will also present novel experimental findings, that for the first time, characterize the ex vivo effect of Methylene Blue on mitochondrial function in synaptic and non-synaptic populations of mitochondria.

UR - http://www.scopus.com/inward/record.url?scp=85017439811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017439811&partnerID=8YFLogxK

U2 - 10.1016/j.neuint.2017.04.004

DO - 10.1016/j.neuint.2017.04.004

M3 - Short survey

VL - 109

SP - 117

EP - 125

JO - Neurochemistry International

JF - Neurochemistry International

SN - 0197-0186

ER -